Brief: Guardant Health Q2 Adjusted EPS USD -0.44 Vs. IBES Estimate USD -0.79

Guardant Health

30/07/2025 21:05

Overview

Guardant Health Q2 2025 revenue rises 31%, beating analyst expectations, per LSEG data

The precision medicine company focused on improving cancer raises 2025 revenue guidance to $915-$925 mln

Outlook

Guardant Health raises 2025 revenue guidance to $915-$925 mln

Company expects 2025 oncology revenue to grow 20% year-over-year

Screening revenue now expected at $55-$60 mln for 2025

Biopharma & Data revenue growth expected in mid-teens for 2025

Result Drivers

ONCOLOGY GROWTH - Driven by 30% increase in test volume and improved reimbursement rates

SCREENING DEMAND - Strong demand for Shield tests, contributing to revenue growth

BIOPHARMA & DATA - Revenue growth supported by increased test volumes and higher average selling prices

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Beat
$232.10 mln
$211.20 mln (21 Analysts)
Q2 Adjusted EPS
Beat
-$0.44
-$0.79 (14 Analysts)
Q2 EPS
-$0.8
Q2 Adjusted Net Income
Beat
-$55 mln
-$98.60 mln (12 Analysts)
Q2 Adjusted EBITDA
Beat
-$51.90 mln
-$58.10 mln (15 Analysts)

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 23 "strong buy" or "buy", 2 "hold" and 1 "sell" or "strong sell"

The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

Wall Street's median 12-month price target for Guardant Health Inc is $60.00, about 27.8% above its July 29 closing price of $43.32

Press Release: ID:nBw9tH8mja

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)